JPS58103312A - 難溶性医薬品の注射剤用水溶液 - Google Patents
難溶性医薬品の注射剤用水溶液Info
- Publication number
- JPS58103312A JPS58103312A JP56201934A JP20193481A JPS58103312A JP S58103312 A JPS58103312 A JP S58103312A JP 56201934 A JP56201934 A JP 56201934A JP 20193481 A JP20193481 A JP 20193481A JP S58103312 A JPS58103312 A JP S58103312A
- Authority
- JP
- Japan
- Prior art keywords
- injection
- acid
- aqueous solution
- aspartic acid
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002347 injection Methods 0.000 title claims abstract description 15
- 239000007924 injection Substances 0.000 title claims abstract description 15
- 239000007864 aqueous solution Substances 0.000 title claims abstract description 12
- 239000003814 drug Substances 0.000 title description 6
- 229940079593 drug Drugs 0.000 title description 5
- 238000002360 preparation method Methods 0.000 title description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract description 15
- 229960005261 aspartic acid Drugs 0.000 claims abstract description 15
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims abstract description 14
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 12
- 239000000203 mixture Substances 0.000 abstract description 2
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 abstract 2
- 210000004051 gastric juice Anatomy 0.000 abstract 2
- 230000028327 secretion Effects 0.000 abstract 2
- 229940126701 oral medication Drugs 0.000 abstract 1
- 229940126062 Compound A Drugs 0.000 description 20
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 20
- 239000002253 acid Substances 0.000 description 14
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 9
- 239000013078 crystal Substances 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 239000001530 fumaric acid Substances 0.000 description 3
- 235000006408 oxalic acid Nutrition 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000003381 solubilizing effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- -1 2-diaminomethyleneaminothiazol-4-yl Chemical group 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56201934A JPS58103312A (ja) | 1981-12-15 | 1981-12-15 | 難溶性医薬品の注射剤用水溶液 |
| ES518199A ES8405613A1 (es) | 1981-12-15 | 1982-12-14 | Un procedimiento para producir una composicion inyectable acuosa de famotidina. |
| CA000417637A CA1184495A (en) | 1981-12-15 | 1982-12-14 | Process of producing pharmaceutical composition of famotidine for injection |
| GR70069A GR77823B (cs) | 1981-12-15 | 1982-12-14 | |
| PT75985A PT75985B (en) | 1981-12-15 | 1982-12-14 | Process to produce a pharmaceutical composition of famotidine for injection |
| MX82101115U MX7581E (es) | 1981-12-15 | 1982-12-15 | Procedimiento para preparar una composicion farmaceutica a base de famotidina |
| KR8205621A KR880001632B1 (en) | 1981-12-15 | 1982-12-15 | Process for preparing famotidino injection composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56201934A JPS58103312A (ja) | 1981-12-15 | 1981-12-15 | 難溶性医薬品の注射剤用水溶液 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58103312A true JPS58103312A (ja) | 1983-06-20 |
| JPS6365047B2 JPS6365047B2 (cs) | 1988-12-14 |
Family
ID=16449204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56201934A Granted JPS58103312A (ja) | 1981-12-15 | 1981-12-15 | 難溶性医薬品の注射剤用水溶液 |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JPS58103312A (cs) |
| KR (1) | KR880001632B1 (cs) |
| CA (1) | CA1184495A (cs) |
| ES (1) | ES8405613A1 (cs) |
| GR (1) | GR77823B (cs) |
| MX (1) | MX7581E (cs) |
| PT (1) | PT75985B (cs) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4749790A (en) * | 1985-06-28 | 1988-06-07 | Barisintex, S.A | Process for preparing H2 receptor antagonist ascorbate compounds |
| WO2002041892A1 (en) * | 2000-11-24 | 2002-05-30 | Yamanouchi Pharmaceutical Co., Ltd. | Water-soluble liquid internal medicine |
| WO2003055483A1 (fr) * | 2001-12-27 | 2003-07-10 | Terumo Kabushiki Kaisha | Solution d'injection de famotidine |
| WO2003094889A1 (fr) * | 2002-05-13 | 2003-11-20 | Daiichi Pharmaceutical Co., Ltd. | Produit de lyophilisation |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1352654E (pt) * | 2000-12-22 | 2006-06-30 | Astellas Pharma Inc | Injeccoes de famotidina. |
| JP4828040B2 (ja) * | 2001-04-27 | 2011-11-30 | テルモ株式会社 | ファモチジン注射液 |
| CN111904936B (zh) * | 2020-08-28 | 2022-07-19 | 开封康诺药业有限公司 | 一种法莫替丁冻干粉针剂 |
| CN114681409A (zh) * | 2021-10-20 | 2022-07-01 | 海南倍特药业有限公司 | 一种注射用法莫替丁及其制备方法 |
| CN114028342B (zh) * | 2021-12-08 | 2023-04-28 | 广东彼迪药业有限公司 | 一种法莫替丁速崩颗粒、法莫替丁片及制备方法 |
-
1981
- 1981-12-15 JP JP56201934A patent/JPS58103312A/ja active Granted
-
1982
- 1982-12-14 ES ES518199A patent/ES8405613A1/es not_active Expired
- 1982-12-14 GR GR70069A patent/GR77823B/el unknown
- 1982-12-14 PT PT75985A patent/PT75985B/pt unknown
- 1982-12-14 CA CA000417637A patent/CA1184495A/en not_active Expired
- 1982-12-15 KR KR8205621A patent/KR880001632B1/ko not_active Expired
- 1982-12-15 MX MX82101115U patent/MX7581E/es unknown
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4749790A (en) * | 1985-06-28 | 1988-06-07 | Barisintex, S.A | Process for preparing H2 receptor antagonist ascorbate compounds |
| WO2002041892A1 (en) * | 2000-11-24 | 2002-05-30 | Yamanouchi Pharmaceutical Co., Ltd. | Water-soluble liquid internal medicine |
| WO2003055483A1 (fr) * | 2001-12-27 | 2003-07-10 | Terumo Kabushiki Kaisha | Solution d'injection de famotidine |
| WO2003094889A1 (fr) * | 2002-05-13 | 2003-11-20 | Daiichi Pharmaceutical Co., Ltd. | Produit de lyophilisation |
Also Published As
| Publication number | Publication date |
|---|---|
| ES518199A0 (es) | 1984-06-16 |
| ES8405613A1 (es) | 1984-06-16 |
| JPS6365047B2 (cs) | 1988-12-14 |
| PT75985A (en) | 1983-01-01 |
| KR880001632B1 (en) | 1988-09-03 |
| PT75985B (en) | 1985-12-05 |
| KR840002654A (ko) | 1984-07-16 |
| MX7581E (es) | 1989-11-24 |
| GR77823B (cs) | 1984-09-25 |
| CA1184495A (en) | 1985-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW442295B (en) | Stable freeze-dried pharmaceutical composition | |
| JPS6191116A (ja) | 安定化された注射用ピロキシカム液剤 | |
| JPS6094910A (ja) | ピペラジニル―キノロンカルボン酸の乳酸塩の溶液 | |
| JPS58103312A (ja) | 難溶性医薬品の注射剤用水溶液 | |
| JP4543679B2 (ja) | 唯一の共同溶剤としてプロピレングリコールを含んでいる使用準備ができているパラセタモール注射溶液 | |
| EP2131845A1 (en) | Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms | |
| WO1994013281A1 (fr) | Preparation en gel a action anti-inflammatoire et analgesique | |
| US20080233196A1 (en) | Injectable sterile pharmaceutical composition with piperacillin sodium and tazobactam sodium as active principles | |
| JPH0131390B2 (cs) | ||
| JPH07503941A (ja) | スパルフロキサシンの溶液、その調製及びそれから成る塩 | |
| NO153916B (no) | Fremgangsmaate for fremstilling av en stabil, injiserbar opploesning av et oksytetracyklin-chelat. | |
| CA1170571A (en) | Pharmaceutical compositions | |
| JP2001163776A (ja) | 安定化された液剤 | |
| JP2635009B2 (ja) | 安定なエルカトニン製剤 | |
| JP2001519390A (ja) | 安定剤としてグリシンを含む製薬学的製剤 | |
| KR920006911B1 (ko) | 안정한 피록시캄 주사액 조성물 및 그의 제조방법 | |
| AU670838B2 (en) | Soluble calcium lactate/quindonecarboxylic acids on naphthydrinecarboxylic acids complexes as non-irritating parenteral forms | |
| JP4296374B2 (ja) | 安定な液状製剤 | |
| JP4193218B2 (ja) | ビオチンの溶解方法及びビオチン含有内服液剤 | |
| JPH11193234A (ja) | ニカルジピンの液状医薬品製剤 | |
| JP2002322057A (ja) | ファモチジン注射液 | |
| JPH0390019A (ja) | 製薬学的活性物質の非経口的投与可能な溶液の調製方法 | |
| RU2185152C1 (ru) | Способ приготовления суспензии фармацевтической композиции на основе субстанции генно-инженерного (рекомбинантного) инсулина человека | |
| JPH0118051B2 (cs) | ||
| JP2002542288A (ja) | 注射可能な新規抗凝固薬組成物 |